Supply of Imiquimod (Aldara) by iNova Pharmaceuticals

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that such goods meet safety, quality, and efficacy standards. This legislation was introduced to address the need for a comprehensive regulatory framework that governs the approval, manufacture, and distribution of therapeutic products, encompassing medicines, medical devices, and other health-related goods. The Therapeutic Goods Administration, operating under the auspices of the Department of Health, administers the Act and is responsible for enforcing its provisions. The policy objective underpinning the Act is to protect public health by ensuring that all therapeutic goods available in Australia are of acceptable quality and pose no undue risk to consumers when used according to their intended purpose. In specific instances, such as the case noted in the Gazette entry for October 9, 2013, the Act facilitates the conditional approval of products that do not fully conform to certain pharmacopoeial standards but meet other critical safety and quality benchmarks.

Scope and Application

The Therapeutic Goods Act 1989, under which the Therapeutic Goods Administration (TGA) operates, encompasses a broad range of therapeutic goods, including medicines, medical devices, blood, and tissues, with the overarching aim of ensuring their safety, quality, and efficacy. Section 14 and 14A of the Act provides the legal framework for the TGA to issue consents for the supply of therapeutic goods that may not fully comply with specific standards, such as those set out in Therapeutic Goods Orders (TGOs). The legislation applies to entities and products within Australia, including companies like iNova Pharmaceuticals Pty Ltd, and the consent granted extends to specific products like imiquimod (ALDARA) 50 mg/g cream pump, which in this case, did not meet the preservative efficacy testing requirements as stipulated in TGO 77 concerning A. brasiliensis. The application of the Act is subject to conditions that ensure any non-compliance does not compromise the safety and efficacy of the therapeutic goods supplied within Australia.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, allows the delegate of the Secretary of the Department of Health to consent to the supply of a therapeutic good that does not fully comply with certain standards, subject to specific conditions. In this instance, the Secretary's delegate has given consent for the supply of imiquimod (ALDARA) 50 mg/g cream pump (Aust R 191815) by iNova Pharmaceuticals Pty Ltd, provided the product meets all other requirements of Therapeutic Goods Order (TGO) 77. This consent is limited by the condition that the product must adhere to all other applicable requirements of TGO 77, which pertains to microbiological standards for medicines. Entities such as iNova Pharmaceuticals Pty Ltd, who are granted consent under these sections, must ensure that their product meets the comprehensive criteria set forth in TGO 77, except for the specific preservative efficacy testing requirement that has been relaxed. They are obligated to provide sufficient evidence that the product complies with all other standards to satisfy regulatory requirements and maintain the integrity and safety of the therapeutic goods supplied to the Australian market. Failure to comply with the conditions set by the Secretary’s delegate may lead to severe consequences. While specific offences, penalties, or consequences are not outlined in the notice, breaches of the Therapeutic Goods Act 1989 and associated regulations can result in significant civil or criminal penalties. The Act provides for hefty fines and potential imprisonment for individuals found guilty of serious offences, alongside substantial fines for corporations. Furthermore, the Therapeutic Goods Administration (TGA) has the authority to issue infringement notices for less severe breaches, which can incur fines up to certain monetary limits specified in the Act. Additionally, the TGA can take action to suspend or cancel the Australian Register of Therapeutic Goods (ARTG) entry for the non-compliant product, which would effectively halt its supply in Australia. This action can have severe commercial repercussions for the entity involved, including loss of market presence and potential revenue. Therefore, it is imperative for entities to adhere strictly to the conditions and requirements stipulated by the Act and the TGA to avoid these consequences.